Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease : An ENEIDA Registry Study
Guerra, Iván (Hospital Universitario de Fuenlabrada ( Madrid))
Bujanda, Luis (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Mañosa i Ciria, Míriam (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pérez-Martínez, Isabel (Instituto de Investigación Sanitaria del Principado de Asturias)
Casanova, María José (Instituto de Investigación Hospital Universitario de la Princesa)
de la Peña, Luisa (Institut d'Investigació Biomèdica de Bellvitge)
de Benito, Marina (Hospital Universitario Río Hortega (Valladolid))
Rivero, Montserrat (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Varela, Pilar (Hospital Universitario de Cabueñes (Gijón))
Bernal, Lorena (Hospital General Universitario Dr Balmis de Alicante)
Franco, Ana Carolina (Hospital Universitario de Fuenlabrada ( Madrid))
Ber, Yolanda (Hospital General San Jorge (Huesca, Espanya))
Piqueras, Marta (Consorci Sanitari Terrassa)
Tardillo, Carlos (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife))
Ponferrada, Ángel (Hospital Universitario Infanta Leonor)
Olivares, Sonsoles (Hospital Universitario 12 de Octubre (Madrid))
Lucendo, Alfredo J. (Hospital General de Tomelloso (Ciudad Real, Espanya))
Gilabert, Pau (Hospital de Viladecans (Barcelona, Espanya))
Sierra Ausín, Mónica (Complejo Asistencial Universitario de León)
Bellart, María (Hospital Universitario de Fuenlabrada ( Madrid))
Herrarte, Amaia (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Calafat, Margalida (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
de Francisco, Ruth (Hospital Universitario Central de Asturias (Oviedo, Espanya))
P. Gisbert, Javier (Instituto de Investigación Hospital Universitario de la Princesa)
Guardiola, Jordi (Institut d'Investigació Biomèdica de Bellvitge)
Domènech, Eugeni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bermejo, Fernando (Hospital Universitario de Fuenlabrada ( Madrid))
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	An increased risk of hematological malignancies, mainly lymphomas, has been described in patients with inflammatory bowel disease (IBD). Because there are scarce data about the management and evolution of lymphomas in patients with IBD, the aim of our study was to analyze these points in those patients with IBD and lymphoma diagnosis included in the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2. 4 cases of lymphoma/1000 patients with IBD). We found that most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies. The five-year survival rate was 85% for non-Hodgkin lymphoma and 84% in patients with Hodgkin lymphoma. An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2. 4 cases of lymphoma/1000 patients with IBD; 95% CI 1. 8-3. 1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0. 05). Five cases had relapse of lymphoma (1. 7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Inflammatory bowel disease ; Lymphoma ; Thiopurines ; Anti-TNF
Publicado en:	Cancers, Vol. 15 (january 2023) , ISSN 2072-6694

DOI: 10.3390/cancers15030750
PMID: 36765708

10 p, 571.4 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados